Company / SG&A Expense
Terns Pharmaceuticals, Inc. SG&A Expense History
FY2020-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$31.8M
FY2024
5-year range
$9.0M / $39.1M
FY2020-FY2024
Trend
-18.7%
vs FY2023
Sector context
#178 of 212
Health Care
What the data says
Terns Pharmaceuticals, Inc.'s sg&a expense of $32M is lower than 84% of companies in the Health Care sector (FY2024). Increased from $22M to $32M over the past 2 years.
Based on SEC 10-K filings.
$32M in FY2024 with a 3-year CAGR of +17.6%.
Increased from $22M to $32M over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +17.6%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Top 16% in Health CareTop 16% of 212This company $31.8M Sector average $722.9M
▼
-95.6% below sector average
Key checks
Key Insights
- 3-year CAGR of +17.6%, indicating consistent growth.
- In FY2024, sg&a expense decreased 18.7% year-over-year.
- Ranks #178 out of 212 companies in the Health Care sector.
- Peak sg&a expense was recorded in FY2023.
Company context
Key Data Points
- Altman Z-Score 7.86 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $31.8M | -18.7% |
| FY2023 | $39.1M | +74.3% |
| FY2022 | $22.4M | +14.6% |
| FY2021 | $19.5M | +117.3% |
| FY2020 | $9.0M | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026